{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01795950",
      "OrgStudyIdInfo": {
        "OrgStudyId": "PLX-PH-101"
      },
      "Organization": {
        "OrgFullName": "United Therapeutics",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)",
      "OfficialTitle": "A Phase I Safety and Pharmacodynamic Study of Intravenous Infusion of PLX-PAD Cells in Patients With PAH"
    },
    "StatusModule": {
      "StatusVerifiedDate": "February 2016",
      "OverallStatus": "Terminated",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "April 2013"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2015",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "January 2016",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "February 12, 2013",
      "StudyFirstSubmitQCDate": "February 18, 2013",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "February 21, 2013",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "February 15, 2016",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "February 17, 2016",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "United Therapeutics",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose of this clinical study is to assess the safety of PLX-PAD to treat pulmonary arterial hypertension (PAH). PLX-PAD is a cell-based product made of allogeneic Mesenchymal-like Adherent Stromal Cells (ASCs), derived from human full-term placentas following an elective caesarean section. This year-long study will evaluate the safety of three different dose levels of PLX-PAD, each given as a single intravenous infusion. This study will also evaluate effects that PLX-PAD may have on PAH, such as changes in the ability to exercise and on other tests used to measure the disease severity."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Pulmonary Arterial Hypertension"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "cell therapy",
          "Pulmonary arterial hypertension"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "6",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "0.5 M PLX-PAD",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "0.5 million (M) PLX-PAD cells per kg body weight",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: PLX-PAD"
              ]
            }
          },
          {
            "ArmGroupLabel": "1 M PLX-PAD",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "1.0 million (M) PLX-PAD cells per kg body weight",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: PLX-PAD"
              ]
            }
          },
          {
            "ArmGroupLabel": "2 M PLX-PAD",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "2.0 million (M) PLX-PAD cells per kg body weight",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: PLX-PAD"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "PLX-PAD",
            "InterventionDescription": "intravenous administration of a single dose of PLX-PAD cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "0.5 M PLX-PAD",
                "1 M PLX-PAD",
                "2 M PLX-PAD"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "allogeneic Mesenchymal-like Adherent Stromal Cells (ASCs)"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Incidence of treatment-emergent AEs (frequency and severity at each dose level)",
            "PrimaryOutcomeTimeFrame": "12 weeks"
          },
          {
            "PrimaryOutcomeMeasure": "Incidence of SAEs",
            "PrimaryOutcomeTimeFrame": "1 year"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Change in Six Minute Walk distance",
            "SecondaryOutcomeTimeFrame": "Baseline and 6 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Change in Dyspnea Score",
            "SecondaryOutcomeDescription": "Change in maximum level of dyspnea experienced during the six minute walk test using a 10 point scale.",
            "SecondaryOutcomeTimeFrame": "Baseline and 6 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Change in WHO Functional Classification",
            "SecondaryOutcomeTimeFrame": "Baseline and 6 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Change in Plasma NT-pro-BNP levels",
            "SecondaryOutcomeTimeFrame": "Baseline and 6 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Change from Baseline in echocardiography parameters",
            "SecondaryOutcomeDescription": "Change in RV area at end systole and end diastole (for calculation of estimated RV ejection fraction, RV basal and mid diameter at end systole and end diastole, RV free wall thickness, tricuspid annular plane systolic excursion (TAPSE), maximal tricuspid regurgitant jet velocity TRJV) and pulmonary artery end diastolic pressure (PAEDP)",
            "SecondaryOutcomeTimeFrame": "Baseline and 6 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Change in cardiopulmonary hemodynamics",
            "SecondaryOutcomeDescription": "mean pulmonary arterial pressure (PAPm), heart rate (HR), systolic systemic arterial pressure (SAPs), diastolic systemic arterial pressure (SAPd), mean systemic arterial pressure (SAPm), pulmonary artery systolic pressure (PAPs), pulmonary artery diastolic pressure (PAPd), mean right atrial pressure (RAPm), mean pulmonary capillary wedge pressure (PCWPm), and cardiac output (CO)",
            "SecondaryOutcomeTimeFrame": "Baseline and 6 weeks"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Summary of inclusion and exclusion criteria.\n\nEligible subjects:\n\nAre between 18 and 75 years of age\nHave a minimum weight of 45 kg\nHave a diagnosis of idiopathic or heritable PAH, PAH associated with connective tissue disease (CTD), PAH associated with repaired congenital systemic-to-pulmonary cardiac shunt (at least one year since repair), or PAH associated with appetite suppressant/drug or toxin use confirmed by RHC\nHave a current WHO functional class II or III designation\nHave been stabilized, without dose changes for at least 30 days prior to the Screening visit on at least two approved PAH medications (e.g., PDE-5 inhibitor, ERA, prostanoid [as inhalation or infusion]); or IV prostanoid monotherapy. Subjects on an IV prostanoid must have been receiving therapy for at least three months prior to the Screening visit.\nHave a 6MWD equal to or greater than 200 meters (m) at the Screening and Baseline Visits.\n\nSubjects must not:\n\nHave any evidence of pulmonary thrombus, significant coronary artery disease (CAD), left ventricular dysfunction, or a restrictive or congestive cardiomyopathy\nHave a history of malignancies within the past 5 years,with the exception of individuals with localized, non-metastatic basal cell carcinoma of the skin, in situ carcinoma of the cervix, or prostate cancer who are not currently or expected to undergo radiation therapy, chemotherapy and/or surgical intervention, or to initiate hormonal treatment during the study\nBe listed for transplantation\nBe pregnant or nursing",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "75 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Daniel Chambers, MRCP FRACP MD",
            "OverallOfficialAffiliation": "The Prince Charles Hospital",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "The Prince Charles Hospital",
            "LocationCity": "Brisbane",
            "LocationState": "Queensland",
            "LocationZip": "4032",
            "LocationCountry": "Australia"
          },
          {
            "LocationFacility": "The Alfred Hospital",
            "LocationCity": "Melbourne",
            "LocationCountry": "Australia"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000081029",
            "ConditionMeshTerm": "Pulmonary Arterial Hypertension"
          },
          {
            "ConditionMeshId": "D000065627",
            "ConditionMeshTerm": "Familial Primary Pulmonary Hypertension"
          },
          {
            "ConditionMeshId": "D000006973",
            "ConditionMeshTerm": "Hypertension"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000014652",
            "ConditionAncestorTerm": "Vascular Diseases"
          },
          {
            "ConditionAncestorId": "D000002318",
            "ConditionAncestorTerm": "Cardiovascular Diseases"
          },
          {
            "ConditionAncestorId": "D000006976",
            "ConditionAncestorTerm": "Hypertension, Pulmonary"
          },
          {
            "ConditionAncestorId": "D000008171",
            "ConditionAncestorTerm": "Lung Diseases"
          },
          {
            "ConditionAncestorId": "D000012140",
            "ConditionAncestorTerm": "Respiratory Tract Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M9176",
            "ConditionBrowseLeafName": "Hypertension",
            "ConditionBrowseLeafAsFound": "Arterial Hypertension",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M2262",
            "ConditionBrowseLeafName": "Pulmonary Arterial Hypertension",
            "ConditionBrowseLeafAsFound": "Pulmonary Arterial Hypertension",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9179",
            "ConditionBrowseLeafName": "Hypertension, Pulmonary",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M29694",
            "ConditionBrowseLeafName": "Familial Primary Pulmonary Hypertension",
            "ConditionBrowseLeafAsFound": "Pulmonary Arterial Hypertension",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M16552",
            "ConditionBrowseLeafName": "Vascular Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10320",
            "ConditionBrowseLeafName": "Lung Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14129",
            "ConditionBrowseLeafName": "Respiratory Tract Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T4807",
            "ConditionBrowseLeafName": "Pulmonary Arterial Hypertension",
            "ConditionBrowseLeafAsFound": "Pulmonary Arterial Hypertension",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC14",
            "ConditionBrowseBranchName": "Heart and Blood Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC08",
            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}